Patent application number | Description | Published |
20080234198 | Selective Vpac2 Receptor Peptide Agonists - The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. | 09-25-2008 |
20080318845 | Selective Vpac2 Receptor Peptide Agonists - The present invention relates to peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. | 12-25-2008 |
20090082276 | SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS - The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. | 03-26-2009 |
20090118167 | Selective Vpac2 Receptor Peptide Agonists - The invention provides VPAC2R peptide agonists coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. | 05-07-2009 |
20100009916 | SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS - The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. | 01-14-2010 |
20100048460 | SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS - The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. | 02-25-2010 |
20110152181 | OXYNTOMODULIN PEPTIDE ANALOGUE - The present invention provides Oxyntomodulin peptide analogues useful in the treatment of diabetes and/or obesity. | 06-23-2011 |
20110152182 | OXYNTOMODULIN PEPTIDE ANALOGUE - The present invention provides an Oxyntomodulin peptide analogue useful in the treatment of diabetes and/or obesity. | 06-23-2011 |
20110237503 | NOVEL PEPTIDES AND METHODS FOR THEIR PREPARATION AND USE - The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity for both GIP-R and GLP-1-R and maintain selectivity over Gluc-R. | 09-29-2011 |
20140056893 | Homodimeric Proteins - This present invention relates to a homodimeric protein comprising fibroblast growth factor 21 (FGF21) and glucagon-like peptide (GLP-1), pharmaceutical compositions comprising the homodimeric protein, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such homodimeric protein. | 02-27-2014 |